Mycobacterium marinum skin infection in a patient treatment with natalizumab;Infección cutánea por Mycobacterium marinum en un paciente en tratamiento con natalizumab

Revista de Neurologia

Volumn 52, Issue 11, 2011, Pages 701-702

  Fernández, Luciana Midaglia ^a   Muñoz García, Delicias ^a   Sopeña, Bernardo ^b   Rodríguez Cerdeira, Carmen ^a  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^b Unidad de Trombosis y Vasculitis   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

HUMAN; MYCOBACTERIUM; NOTE; SKIN DISEASE; SKIN INFECTION; ATYPICAL MYCOBACTERIOSIS; BACTERIAL SKIN DISEASE; CASE REPORT; FEMALE; LETTER; MICROBIOLOGY; MIDDLE AGED; MULTIPLE SCLEROSIS; MYCOBACTERIUM MARINUM; PATHOGENICITY;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM MARINUM; SKIN DISEASES, BACTERIAL;

EID: 79958265088     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5211.2011109     Document Type: Note

References (12)

1. Río-Izquierdo J, Montalban X. Natalizumab en esclerosis múltiple. Rev Neurol 2009; 49: 265-9.
2. Horga A, Castillo J, Río J, Tintoré M, Auger-Acosta C, Sastre-Garriga J, et al. Estudio observacional sobre la efectividad y seguridad del natalizumab en el tratamiento de la esclerosis múltiple. Rev Neurol 2011; 52: 321-30.
3. Goodin D, Cohen B, O'Connor P, Kappos L, Stevens J. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidencebased review). Neurology 2008; 71: 766-73.
4. Petrini B. Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections. Eur J Clin Microbiol Infect Dis 2006; 25: 609-13.
5. Pui-Yin CJ, Fung B, Sai-Yin WS. Mycobacterium marinum infection of the hand and wrist. J Orthop Surg 2010; 18: 98-103.
6. García-Acebes C, Barchino-Ortiz L, Aboín-González S, Díaz-Ley B. Infección por Mycobacterium marinum, presentación de un nuevo caso y revisión de la literatura. Actas Dermosifiliogr 2006; 97: 653-7.
7. Jernigan J, Farr B. Incubation period and sources of exposure for cutaneous Mycobacterium marinum infection. Clin Infect Dis 2000; 31: 439-43.
8. Chen H, Chen C, Huang C, Ruan S, Chou C, Lai C, et al. Skin and soft-tissue infection caused by non-tuberculous mycobacteria in Taiwan, 1997-2008. Epidemiol Infect 2011; 139: 121-9.
9. Ang P. Rattana-Apiromikaij N, Goh C. Retrospective study of Mycobacterium marinum skin infections. Int J Dermatol 2000; 39: 343-7.
10. Lee J, Reinke EK, Zozulya AL, Sandor M, Fabry Z. Mycobacterium bovis bacille Calmette-Guérin infection in the CNS suppresses experimental autoimmune encephalomyelitis and Th17 responses in an IFN-gammaindependent manner. J Immunol 2008; 181: 6201-12.
11. Danko J, Gilliland W. Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy. Scand J Infect Dis 2009; 41: 252-5.
12. Guyot A, Begon E, Abramowitz L. A case of acute and necrotizing cutaneous Mycobacterium marinum infection in a patient treated with infliximab for Crohn's disease. Ann Dermatol Venereol 2009; 136: 806-10.